The abstract is read at the publisher; the summary is JClub's.
Baseline FDG PET/CT detected non-central nervous system extramedullary disease in 44% of 16 adults and children with relapsed/refractory B-ALL.
- Why it matters: Whole-body imaging is not routine, so the incidence of non-CNS EMD in relapsed/refractory B-ALL is unclear, limiting accurate assessment before CAR T-cell therapy.
- What they did: In a prospective single-center cohort (NCT05969002), patients underwent baseline FDG PET/CT before CAR T infusion, with post-treatment imaging for those with non-CNS EMD; cfDNA was tracked longitudinally using personalized droplet digital PCR and compared with flow cytometry and next-generation sequencing.
- The result: Non-CNS EMD was multifocal in all affected patients, with median SUVmax 17 (range 13.4–32.3), and cfDNA identified isolated non-CNS EMD in 3 patients despite negative results from other biomarker testing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.